Artiva Biotherapeutics Inc
ARTV4.565USD
-0.175-3.69%
Market hours （ET）Quotes delayed by 15 min
112.05MMarket Cap
LossP/E TTM
More Details of Artiva Biotherapeutics Inc Company
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Artiva Biotherapeutics Inc Info
Ticker SymbolARTV
Company nameArtiva Biotherapeutics Inc
IPO dateJul 19, 2024
CEOAslan (Fred)
Number of employees89
Security typeOrdinary Share
Fiscal year-endJul 19
Address5505 Morehouse Drive
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18582674467
Websitehttps://www.artivabio.com/
Ticker SymbolARTV
IPO dateJul 19, 2024
CEOAslan (Fred)
Company Executives of Artiva Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
39.59K
-3.36%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
2.41K
-35.76%
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Dr. Alison Moore, Ph.D.
Dr. Alison Moore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Fred Aslan, M.D.
Dr. Fred Aslan, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher P. Horan
Mr. Christopher P. Horan
Chief Technical Operations Officer
Chief Technical Operations Officer
--
--
Dr. Brian Daniels, M.D.
Dr. Brian Daniels, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Heather Raymon, Ph.D.
Dr. Heather Raymon, Ph.D.
Senior Vice President - Research and Early Development
Senior Vice President - Research and Early Development
39.59K
-3.36%
Ms. Neha Krishnamohan
Ms. Neha Krishnamohan
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
2.41K
-35.76%
Ms. Jennifer Bush
Ms. Jennifer Bush
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer
--
--
Dr. Laura Stoppel, Ph.D.
Dr. Laura Stoppel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth L. Hougen
Ms. Elizabeth L. Hougen
Independent Director
Independent Director
--
--
Dr. Diego Miralles, M.D.
Dr. Diego Miralles, M.D.
Director
Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q1
FY2022
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Dec 17
Updated: Wed, Dec 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
40.14%
GC Biopharma Corp
18.61%
5AM Ventures
9.59%
VR Adviser, LLC
6.56%
VenBio Partners LLC
4.68%
Other
20.42%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
40.14%
GC Biopharma Corp
18.61%
5AM Ventures
9.59%
VR Adviser, LLC
6.56%
VenBio Partners LLC
4.68%
Other
20.42%
Shareholder Types
Shareholders
Proportion
Venture Capital
56.48%
Corporation
18.61%
Hedge Fund
5.50%
Individual Investor
5.43%
Private Equity
4.68%
Investment Advisor/Hedge Fund
3.68%
Investment Advisor
2.50%
Research Firm
1.28%
Other
1.85%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
113
18.19M
82.07%
+1.82K
2025Q3
113
18.19M
82.47%
-356.42K
2025Q2
106
18.54M
87.44%
-2.45M
2025Q1
93
21.00M
87.08%
-218.92K
2024Q4
86
21.21M
85.45%
+459.05K
2024Q3
67
20.75M
65.99%
+4.72M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
9.85M
40.34%
--
--
Jun 30, 2025
GC Biopharma Corp
4.57M
18.7%
+4.57M
--
Jul 22, 2024
5AM Ventures
2.35M
9.63%
--
--
Jun 30, 2025
VR Adviser, LLC
1.61M
6.59%
--
--
Jun 30, 2025
VenBio Partners LLC
1.15M
4.7%
-50.00K
-4.17%
Jun 30, 2025
Citadel Advisors LLC
153.74K
0.63%
+8.65K
+5.96%
Jun 30, 2025
Franklin Advisers, Inc.
520.33K
2.13%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
457.05K
1.87%
-698.32K
-60.44%
Jun 30, 2025
Millennium Management LLC
327.07K
1.34%
+327.07K
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Nasdaq Biotechnology ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
View more
Invesco Nasdaq Biotechnology ETF
Proportion0.01%
ProShares Ultra Nasdaq Biotechnology
Proportion0.01%
iShares Biotechnology ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Artiva Biotherapeutics Inc?
The top five shareholders of Artiva Biotherapeutics Inc are:
RA Capital Management, LP holds 9.85M shares, accounting for 40.34% of the total shares.
GC Biopharma Corp holds 4.57M shares, accounting for 18.70% of the total shares.
5AM Ventures holds 2.35M shares, accounting for 9.63% of the total shares.
VR Adviser, LLC holds 1.61M shares, accounting for 6.59% of the total shares.
VenBio Partners LLC holds 1.15M shares, accounting for 4.70% of the total shares.
RA Capital Management, LP holds 9.85M shares, accounting for 40.34% of the total shares.
GC Biopharma Corp holds 4.57M shares, accounting for 18.70% of the total shares.
5AM Ventures holds 2.35M shares, accounting for 9.63% of the total shares.
VR Adviser, LLC holds 1.61M shares, accounting for 6.59% of the total shares.
VenBio Partners LLC holds 1.15M shares, accounting for 4.70% of the total shares.
What are the top three shareholder types of Artiva Biotherapeutics Inc?
The top three shareholder types of Artiva Biotherapeutics Inc are:
RA Capital Management, LP
GC Biopharma Corp
5AM Ventures
RA Capital Management, LP
GC Biopharma Corp
5AM Ventures
How many institutions hold shares of Artiva Biotherapeutics Inc (ARTV)?
As of 2025Q4, 113 institutions hold shares of Artiva Biotherapeutics Inc, with a combined market value of approximately 18.19M, accounting for 82.07% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.40%.
What is the biggest source of revenue for Artiva Biotherapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Artiva Biotherapeutics Inc, amounting to -- and accounting for --% of total revenue.
